Hong Kong Stock Movement | VENUS MEDTECH-B (02500) Rises Nearly 8% as Subsidiary Files Patent Infringement Lawsuit in US Against Edwards' Key Product PASCAL

Stock News01-19

VENUS MEDTECH-B (02500) saw its intraday surge exceed 14%. As of the time of writing, the stock was up 7.99%, trading at HK$3.65, with a turnover of HK$26.2799 million. On January 14 local time, Cardiovalve, a subsidiary of Hangzhou-based VENUS MEDTECH, jointly with MTH IP, L.P., filed a patent infringement lawsuit against global heart valve giant Edwards Lifesciences in the US District Court for the District of Delaware. The lawsuit alleges that Edwards' core product, the PASCAL Precision transcatheter valve repair system, infringes upon US Patent No. 10,702,385 ("the '385 patent"), which is owned by Cardiovalve. Analysts pointed out that this legal action represents proactive rights protection by VENUS MEDTECH following its successful defense of the '385 patent's validity against a challenge from Edwards in July 2025. This move is not only a defense of its own innovative achievements but also a landmark case in the globalization of Chinese medical device companies, demonstrating competitive market participation underpinned by a robust intellectual property system.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128190795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-19 15:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128190795","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Movement | VENUS MEDTECH-B (02500) Rises Nearly 8% as Subsidiary Files Patent Infringement Lawsuit in US Against Edwards' Key Product PASCAL","media":"Stock News","content":"<p>VENUS MEDTECH-B (02500) saw its intraday surge exceed 14%. As of the time of writing, the stock was up 7.99%, trading at HK$3.65, with a turnover of HK$26.2799 million.\nOn January 14 local time, Cardiovalve, a subsidiary of Hangzhou-based VENUS MEDTECH, jointly with MTH IP, L.P., filed a patent infringement lawsuit against global heart valve giant Edwards Lifesciences in the US District Court for the District of Delaware.\nThe lawsuit alleges that Edwards' core product, the PASCAL Precision transcatheter valve repair system, infringes upon US Patent No. 10,702,385 (\"the '385 patent\"), which is owned by Cardiovalve.\nAnalysts pointed out that this legal action represents proactive rights protection by VENUS MEDTECH following its successful defense of the '385 patent's validity against a challenge from Edwards in July 2025.\nThis move is not only a defense of its own innovative achievements but also a landmark case in the globalization of Chinese medical device companies, demonstrating competitive market participation underpinned by a robust intellectual property system.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | VENUS MEDTECH-B (02500) Rises Nearly 8% as Subsidiary Files Patent Infringement Lawsuit in US Against Edwards' Key Product PASCAL</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | VENUS MEDTECH-B (02500) Rises Nearly 8% as Subsidiary Files Patent Infringement Lawsuit in US Against Edwards' Key Product PASCAL\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-19 15:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VENUS MEDTECH-B (02500) saw its intraday surge exceed 14%. As of the time of writing, the stock was up 7.99%, trading at HK$3.65, with a turnover of HK$26.2799 million.\nOn January 14 local time, Cardiovalve, a subsidiary of Hangzhou-based VENUS MEDTECH, jointly with MTH IP, L.P., filed a patent infringement lawsuit against global heart valve giant Edwards Lifesciences in the US District Court for the District of Delaware.\nThe lawsuit alleges that Edwards' core product, the PASCAL Precision transcatheter valve repair system, infringes upon US Patent No. 10,702,385 (\"the '385 patent\"), which is owned by Cardiovalve.\nAnalysts pointed out that this legal action represents proactive rights protection by VENUS MEDTECH following its successful defense of the '385 patent's validity against a challenge from Edwards in July 2025.\nThis move is not only a defense of its own innovative achievements but also a landmark case in the globalization of Chinese medical device companies, demonstrating competitive market participation underpinned by a robust intellectual property system.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02500","symbol_name":"启明医疗-B","start_time":0,"source_url":"","article_id":"1128190795","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128190795","pubTimestamp":1768806670,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VENUS MEDTECH-B (02500) saw its intraday surge exceed 14%. As of the time of writing, the stock was up 7.99%, trading at HK$3.65, with a turnover of HK$26.2799 million. On January 14 local time,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02500":"启明医疗-B","BK1100":"医疗保健设备","BK1583":"高瓴概念","BK1574":"生物医药B类股"},"translate_title":"港股动向|启明医疗-B(02500)涨近8%子公司在美对Edwards关键产品PASCAL提起专利侵权诉讼","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02500":1},"content_text":"VENUS MEDTECH-B (02500) saw its intraday surge exceed 14%. As of the time of writing, the stock was up 7.99%, trading at HK$3.65, with a turnover of HK$26.2799 million.\nOn January 14 local time, Cardiovalve, a subsidiary of Hangzhou-based VENUS MEDTECH, jointly with MTH IP, L.P., filed a patent infringement lawsuit against global heart valve giant Edwards Lifesciences in the US District Court for the District of Delaware.\nThe lawsuit alleges that Edwards' core product, the PASCAL Precision transcatheter valve repair system, infringes upon US Patent No. 10,702,385 (\"the '385 patent\"), which is owned by Cardiovalve.\nAnalysts pointed out that this legal action represents proactive rights protection by VENUS MEDTECH following its successful defense of the '385 patent's validity against a challenge from Edwards in July 2025.\nThis move is not only a defense of its own innovative achievements but also a landmark case in the globalization of Chinese medical device companies, demonstrating competitive market participation underpinned by a robust intellectual property system.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128190795","isCrawlerRequest":true}